MyFinsight
Home
Blog
About
Net loss
attributable to common...
-$6,865,143
(-60.53%↓ Y/Y)
Net loss
-$6,750,128
(-57.84%↓ Y/Y)
Accrual of paid-in-kind
dividends on series a...
$115,015
Change in fair value of
warrant liabilities
-$229,221
(-241.74%↓ Y/Y)
Interest income
$52,168
(35148.65%↑ Y/Y)
Grant income
$21,316
(-86.13%↓ Y/Y)
Loss before income
tax provision
-$6,749,828
Deferred income tax
provision
$300
Total other income
(expense)
$39,677
(171.66%↑ Y/Y)
Change in fair value of
contingent consideration
$217,000
Currency exchange gain
-$36,494
(23.15%↑ Y/Y)
Pipe warrant
issuance costs
$9,534
Operating loss
-$6,789,505
(-60.85%↓ Y/Y)
Total operating
expenses
$6,789,505
(60.85%↑ Y/Y)
Research and development
$3,693,865
(43.96%↑ Y/Y)
General and
administrative
$2,536,179
(53.23%↑ Y/Y)
Sepa financing
issuance costs
$559,461
Back
Back
Income Statement
Transcode Therapeutics, Inc. (RNAZ)
Transcode Therapeutics, Inc. (RNAZ)
source: myfinsight.com